Original InvestigationCirculating Omega-3 Fatty Acids and Incident Adverse Events in Patients With Acute Myocardial Infarction
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Sala-Vila is recipient of the Instituto de Salud Carlos III (ISCIII) Miguel Servet fellowship (grant CPII 17/00029). Dr. Bayés-Genís is supported by ISCIII (PI17/01487, PI18/00256 and PIC18/00014); CIBER Cardiovascular (CB16/11/00403) projects, as a part of the National R&D&I Plan, and it was co-funded by ISCIII-Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF). Part of this work was supported by a grant from the California Walnut Commission, Folsom, California (to Dr. Sala-Vila). The funding agencies had no input in the study design, data collection, analyses, or writing and submission of the manuscript. Dr. Sala-Vila has reported grants and support from the California Walnut Commission to attend professional meetings. Dr. Bayés-Genís has reported personal fees from AstraZeneca, Vifor-Fresenius, Novartis, Boehringer Ingelheim, Abbott, Roche Diagnostics, and Critical Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC author instructions page.
- ∗
Drs Lázaro and Rueda contributed equally to this study.